Xenon, a noble gas known for its rather inert nature, is showing potential as a treatment for Alzheimer’s disease, according to a recent study published in Science Translational Medicine. Xenon may activate brain immune cells called microglia, enhancing their ability to break down amyloid plaques and reduce inflammation—key factors in Alzheimer’s. Conducted on mice by a team from Washington University in St. Louis and Brigham and Women’s Hospital in Boston, the study found that inhaled xenon helped microglia regain their ability to break down beta-amyloid proteins. Among other findings, the researchers found that xenon exposure was linked to lower levels of two hallmark Alzheimer’s proteins. This research has sparked a Phase 1 clinical trial to test xenon’s safety in humans. Despite recent disappointments with Alzheimer’s drugs like Aduhelm, xenon’s ability to alter microglial behavior offers a novel therapeutic avenue. If successful in human trials, xenon could provide a straightforward inhalation-based treatment, revolutionizing Alzheimer’s care. However, its efficacy will be confirmed through upcoming clinical trials.

To read more, click here.

[Source: STAT, January 15th, 2025]